YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Completed

Conditions studied: Advanced Melanoma

In brief

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

Key facts

Study ID

NCT02224768

Run by

Bristol-Myers Squibb

People needed

158

Starts

2015-07-01

Expected to finish

2015-11-01

Last updated by the study team

2015-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose

Where it is running

• Bristol-Myers Squibb — Princeton, New Jersey, United States
• Local Institution — St Ives, Cambridgeshire, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.